Famotidine

Brand names: Major Heartburn Relief, Famotidine, ACID REDUCER, careone acid relief, famotidine, FAMOTIDINE, Equate Famotidine, dg health heartburn prevention, acid reducer, topcare acid reducer, Maximum Strength Acid Reducer, TopCare Acid Reducer, acid relief, Calmicid AC Acid Reducer, members mark acid pep, Acid Reducer, Heartburn Relief, Maximum Strength Acid Controller, ACID CONTROLLER, Acid Controller, acid controller, equaline heartburn prevention, CareOne Acid Relief, Pepcid, Pepcid AC, Rugby Famotidine, equate famotidine, Major Heartburn Relief Maximum Strength, Maximum Strength PEPCID AC Icy Cool Mint, good sense acid reducer, acid reducer original strength, dg health acid reducer, AMAZON BASIC CARE ACID REDUCER, Zantac 360, PEPCID AC Maximum Strength, Good Sense Acid Reducer, Zantac 360 Cool Mint, Original strength heartburn prevention, maximum strength, berkley and jensen famotidine, Leader Acid Reducer, foster and thrive acid reducer, basic care acid reducer, heartburn relief, dg health heartburn prevention original strength, Pepcid AC Original Strength, kirkland signature acid controller, basic care heartburn prevention, heartburn relief original strength, heartburn prevention, Acid Reducer Original Strength, Zantac 360 2 per blister 6 blisters, signature care acid controller, Acid Reducer Maximum Strength, acid controller original strength, Acid Controller Original Strength

Warnings

Central Nervous System Adverse Reactions: "Confusion, delirium, hallucinations, disorientation, agitation, seizures, and lethargy" have occurred in elderly patients and those with moderate-to-severe renal impairment; dosage reduction is recommended. Concurrent Gastric Malignancy: Symptom improvement does not exclude gastric cancer presence; evaluate patients with suboptimal response or early relapse. Renal Impairment Warning: QT prolongation risk exists in moderate-to-severe renal impairment patients.

Contraindications

4 CONTRAINDICATIONS Famotidine for oral suspension is contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other histamine-2 (H 2 ) receptor antagonists. History of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other H 2 receptor antagonists. (4)

Overdose

10 OVERDOSAGE The types of adverse reactions in overdosage of famotidine are similar to the adverse reactions encountered with use of recommended dosages [see ADVERSE REACTIONS (6.1) ]. In the event of overdosage, treatment should be symptomatic and supportive. Unabsorbed material should be removed from the gastrointestinal tract, the patient should be monitored, and supportive therapy should be employed. Due to low binding to plasma proteins, famotidine is eliminated by hemodialysis. There is limited experience on the usefulness of hemodialysis as a treatment for famotidine overdosage.

Drug interactions

7 DRUG INTERACTIONS Drugs Dependent on Gastric pH for Absorption: Systemic exposure of the concomitant drug may be significantly reduced leading to loss of efficacy. See full prescribing information for a list of interacting drugs. (7.1) Tizanidine (CYP1A2) Substrate: Potential for substantial increases in blood concentrations of tizanidine resulting in hypotension, bradycardia or excessive drowsiness; avoid concomitant use, if possible. (7.2) 7.1 Drugs Dependent on Gastric pH for Absorption Famotidine can reduce the absorption of other drugs, due to its effect on reducing intragastric acidity, leading to loss of efficacy of the concomitant drug. Concomitant administration of famotidine for oral suspension with dasatinib, delavirdine mesylate, cefditoren, and fosamprenavir is not recommended. See the prescribing information for other drugs dependent on gastric pH for absorption for administration instructions, including atazanavir, erlotinib, ketoconazole, itraconazole, ledipasvir/sofosbuvir, nilotinib, and rilpivirine. 7.2 Tizanidine (CYP1A2 Substrate) Although not studied clinically, famotidine is considered a weak CYP1A2 inhibitor and may lead to substantial increases in blood concentrations of tizanidine, a CYP1A2 substrate. Avoid concomitant use with famotidine for oral suspension. If concomitant use is necessary, monitor for hypotension, bradycardia or excessive drowsiness. Refer to the full prescribing information for tizanidine.

Uses

Famotidine tablets treat active duodenal and gastric ulcers, symptomatic nonerosive GERD, and erosive esophagitis in patients 40 kg or greater. In adults, it also treats pathological hypersecretory conditions like Zollinger-Ellison syndrome and reduces duodenal ulcer recurrence risk.

Dosage forms & strengths

Tablet Tablet, Film Coated TABLET, FILM COATED INJECTION POWDER TABLET INJECTION, SOLUTION POWDER, FOR SUSPENSION TABLET, COATED FOR SUSPENSION POWDER, FOR SOLUTION GRANULE

FAMOTIDINE 10 mg FAMOTIDINE 20 mg FAMOTIDINE 40 mg FAMOTIDINE 10 mg/1 FAMOTIDINE 20 mg/1 FAMOTIDINE 40 mg/1 FAMOTIDINE 10 mg/mL FAMOTIDINE 1 kg/kg FAMOTIDINE 1 g/g FAMOTIDINE 20 mg/50mL FAMOTIDINE 40 mg/5mL FAMOTIDINE 4 mg/mL FAMOTIDINE 10 mg/10mg FAMOTIDINE 50 kg/50kg FAMOTIDINE 25 kg/25kg FAMOTIDINE 100 mg/1

2 DOSAGE AND ADMINISTRATION Recommended adult dosage by indication (2.1) : Active DU 40 mg once daily; or 20 mg twice daily Active GU 40 mg once daily Symptomatic Nonerosive GERD 20 mg twice daily Erosive Esophagitis due to GERD 20 mg twice daily; or 40 mg twice daily Pathological Hypersecretory Conditions 20 mg every 6 hours; adjust to patient needs; maximum 160 mg every 6 hours Risk Reduction of DU Recurrence 20 mg once daily Recommended pediatric dosage by indication (2.2) : Peptic Ulcer Disease 1 year to less than 17 years Starting dosage 0.5 mg/kg once daily; or 0.25 mg/kg twice daily; may increase to 1 mg/kg once daily at bedtime or 0.5 mg/kg twice daily; Maximum of 40 mg per day GERD Birth to less than 3 months Starting dosage 0.5 mg/kg once daily; may increase to 1 mg/kg once daily 3 months to less than 1 year Starting dosage 0.5 mg/kg twice daily; may increase to 1 mg/kg twice daily; Maximum of 40 mg per day GERD with or without esophagitis and ulcerations 1 year to less than 17 years 0.5 mg/kg twice daily Maximum of 40 mg twice daily See full prescribing information for complete dosing information in adults and pediatrics, recommended treatment duration by indication, and dosage adjustment for adult patients with renal impairment. (2.1 , 2.2 , 2.3) Administration (2.3) : Take once daily before bedtime or twice daily in the morning and before bedtime with or without food. 2.1 Recommended Dosage in Adults The recommended dosage and duration of Famotidine for oral suspension in adults with normal renal function is shown in Table 1. Table 1: Recommended Dosage and Duration of Famotidine for Oral Suspension a in Adults with Normal Renal Function Indication Recommended Dosage Recommended Duration Active DU 40 mg once daily; or 20 mg twice daily b Up to 8 weeks c,d Active GU 40 mg once daily Up to 8 weeks d Symptomatic nonerosive GERD 20 mg twice daily Up to 6 weeks d Erosive esophagitis due to GERD, diagnosed by endoscopy 20 mg twice daily; or 40 mg twice daily b Up to 12 weeks Pathological hypersecretory conditions Starting dosage: 20 mg every 6 hours; adjust dosage to individual patient needs Maximum dosage 160 mg every 6 hours As clinically indicated Reduction of the risk of DU recurrence 20 mg once daily 1 year c,d or as clinically indicated a After preparation, the concentration of famotidine oral suspension is 8 mg/mL [see DOSAGE AND ADMINISTRATION (2.3) ] b Both dosages demonstrated effectiveness in clinical trials [see CLINICAL STUDIES (14) ]. c In clinical trials, the majority of patients healed within 4 weeks. For patients who do not heal after 4 weeks, consider an additional 2 to 4 weeks of treatment [see CLINICAL STUDIES (14.1) ]. d Longer treatment durations have not been studied in clinical trials [see CLINICAL STUDIES (14.1 , 14.2 , 14.3) ]. 2.2 Recommended Dosage in Pediatric Patients The recommended dosage and duration of famotidine for oral suspension in pediatric patients with normal renal function is shown in Table 2. Table 2: Recommended Dosage and Duration of Famotidine for Oral Suspension a in Pediatric Patients with Normal Renal Function Indication Pediatric Age Range Recommended Dosage a Duration Peptic Ulcer Disease 1 year to less than 17 years Starting dosage 0.5 mg/kg once daily; or 0.25 mg/kg twice daily. May increase to 1 mg/kg once daily at bedtime or 0.5 mg/ kg twice daily Maximum of 40 mg per day 8 weeks b GERD Birth to less than 3 months Starting dosage 0.5 mg/kg once daily. May increase to 1 mg/kg once daily b Up to 8 weeks b,c,d 3 months to less than 1 year Starting dosage 0.5 mg/kg twice daily. May increase to 1 mg/kg twice daily c Maximum of 40 mg per day GERD with or without esophagitis and ulcerations 1 year to less than 17 years 0.5 mg/kg twice daily Maximum of 40 mg twice daily 6 to 12 weeks b a After preparation, the concentration of famotidine oral suspension is 8 mg/mL [see DOSAGE AND ADMINISTRATION (2.3) ] b Treatment duration based on adult recommendations (see Table 1). Individualize the dose and duration based upon clinical response an/or pH determinations (gastric or esophageal) and endoscopy. c Use conservative measures (e.g., thickened feedings) concurrently [see USE IN SPECIFIC POPULATIONS (8.4) ]. d After 4 weeks of treatment re-evaluate the patient. Consider an additional 4 weeks of treatment if treatment benefit outweighs potential risks. 2.3 Recommended Dosage in Adults with Renal Impairment Recommended dosage adjustments for adults with moderate to severe renal impairment (creatinine clearance less than 60 mL/min) by indication are shown in Table 3. Use the lowest effective dosage [see USE IN SPECIFIC POPULATIONS (8.6) ]. A safe and effective dosage has not been established in pediatric patients with renal impairment. Table 3: Recommended Maximum Dosage of Famotidine for Oral Suspension in Adults with Moderate and Severe Renal Impairment Indication Recommended Maximum Dosages Creatinine clearance 30 to 60 mL/minute Creatinine clearance less than 30 mL/minute Active DU 20 mg once daily; or 40 mg every other day 10 mg once daily; or 20 mg every other day Active GU 20 mg once daily; or 40 mg every other day 10 mg once daily; or 20 mg every other day Symptomatic nonerosive GERD 20 mg once daily 10 mg once daily; or 20 mg every other day Erosive esophagitis due to GERD, diagnosed by endoscopy a 20 mg once daily; or 40 mg every other day b 40 mg once daily b 10 mg once daily; or 20 mg every other day b 20 mg once daily b Pathological hypersecretory conditions Avoid use b Reduction of the risk of DU recurrence 10 mg once daily; or 20 mg every other day 10 mg every other day a Dosage adjustments for renal impairment are provided for both dosing regimens (20 mg twice daily and 40 mg twice daily) which showed effectiveness for the treatment of erosive esophagitis in clinical trials [see CLINICAL STUDIES (14.4)]. b The dosage required to treat pathological hypersecretory conditions may exceed the maximum dosage evaluated in patients with impaired renal function. The risk for increased adverse reactions in renally impaired patients treated with famotidine for oral suspension for pathological hypersecretory conditions is unknown. 2.4 Administration Instructions Preparation of Constituted Suspension by a Healthcare Provider Prior to Dispensing Prior to dispensing, constitute famotidine for oral suspension by slowly adding 46 mL of Purified Water to the bottle. Shake vigorously for 5 to 10 seconds immediately after adding the water. The constituted suspension contains 40 mg of famotidine per 5 mL, and should be a smooth, mobile, white to off-white, and homogeneous suspension. Administration and Storage of Constituted Suspension Shake the bottle of constituted famotidine for oral suspension vigorously for 5 to 10 seconds prior to each use. Take famotidine for oral suspension once daily before bedtime or twice daily in the morning and before bedtime, as recommended. Famotidine for oral suspension may be taken with or without food [see CLINICAL PHARMACOLOGY (12.3) ] . Famotidine for oral suspension may be given with antacids. Store the constituted suspension at 25°C (77°F). Protect from freezing. Discard unused constituted suspension after 30 days.

Ingredients

Active:

Active ingredient (in each tablet) Famotidine USP 10 mg

Inactive:

Inactive ingredients carnauba wax, corn starch, hydroxypropyl cellulose, hypromellose, magnesium stearate, microcrystalline cellulose, red iron oxide, sodium starch glycolate, talc and titanium dioxide.